H. Sutherland

Matthew P Wright, M. Power, D. Hogge, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia.

S. Nantel, D. Forrest, K. Song, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

S. Tuchman, N. Callander, G. Schiller, 2021, British Journal of Cancer.

Organochlorine Levels in Plasma and Risk of Multiple Myeloma.

J. Spinelli, É. Gaudreau, A. Leblanc, 2018, Journal of occupational and environmental medicine.

Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease

J. Lipton, S. Nantel, S. Nantel, 2005, Bone Marrow Transplantation.

Allografting for indolent lymphoid neoplasms.

D. Reece, J. Connors, S. Nantel, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide.

D. Reece, M. Barnett, H. Klingemann, 1993, Bone marrow transplantation.

A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

M. Dimopoulos, J. Cavenagh, H. van de Velde, 2015, American journal of hematology.

Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures.

C. Eaves, P. Lansdorp, R. Humphries, 1992, The Journal of clinical investigation.

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

J. Shah, D. Reece, P. Neri, 2018, Blood.

Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial

M. Sebag, R. Kotb, M. Lalancette, 2016 .

Hemopoietic stem cell characterization.

C. Eaves, P. Lansdorp, T. Thomas, 1992, Progress in clinical and biological research.

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.

P. Sonneveld, A. Nagler, R. Hájek, 2008, Clinical lymphoma & myeloma.

Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.

J. Kuruvilla, D. Hogge, Clayton A. Smith, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation

J. Kuruvilla, D. Hogge, S. Nantel, 2004, Bone Marrow Transplantation.

Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length

Amanda M Li, R. Schreiber, S. Stockler-Ipsiroglu, 2018, Pediatric hematology and oncology.

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

S. Tuchman, N. Callander, G. Schiller, 2020, EJHaem.

Treatment of myeloma using intensive therapy and allogeneic bone marrow transplantation.

D. Reece, S. Nantel, M. Barnett, 1995, Bone marrow transplantation.

Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens

D. Hogge, S. Nantel, D. Forrest, 2010, Bone Marrow Transplantation.

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.

C. Currie, S. Nantel, C. Toze, 2000, Journal of hematotherapy & stem cell research.

Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium.

R. Kotb, H. Sutherland, M. Louzada, 2020, Clinical lymphoma, myeloma & leukemia.

Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.

John J Spinelli, J. Spinelli, P. Tsang, 2004, Blood.

Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort

M. Power, R. Broady, D. Hogge, 2012 .

Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo.

S. Vercauteren, H. Sutherland, 2004, Blood.

Organochlorine Levels in Plasma and Risk of Multiple Myeloma: Organochlorines and risk of multiple myeloma.

J. Spinelli, É. Gaudreau, A. Leblanc, 2018, Journal of occupational and environmental medicine.

Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy.

D. Reece, S. Nantel, M. Barnett, 1994, Blood.

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

J. Connors, M. Power, R. Broady, 2011, Leukemia & lymphoma.

Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20‐year cohort

J. Connors, M. Power, R. Broady, 2012, British journal of haematology.

Alternative mechanisms with and without steel factor support primitive human hematopoiesis.

C. Eaves, D. Hogge, H. Sutherland, 1993, Blood.

Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia

D. Horsman, H. Bruyèrè, D. Hogge, 2006, Leukemia & lymphoma.

The human hematopoietic stem cell in vitro and in vivo.

C. Eaves, P. Lansdorp, C. Fraser, 1992, Blood cells.

Allogeneic Stem Cell Transplant in First Complete Remission Overcomes the Poor Prognosis Associated with the FLT-3 Internal Tandem Duplication in Acute Myeloid Leukemia.

A. Brooks-Wilson, R. Brinkman, M. Power, 2007 .

Characterization of a hierarchy in human acute myeloid leukemia progenitor cells.

R. Zapf, A. Blair, H. Sutherland, 1996, Blood.

Regulation of primitive human hematopoietic cells in long-term marrow culture.

C. Eaves, P. Lansdorp, R. Humphries, 1991, Seminars in hematology.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

P. Sonneveld, A. Nagler, R. Hájek, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Shifting to outpatient management of acute myeloid leukemia: a prospective experience.

D. Hogge, S. Nantel, D. Forrest, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

P. Richardson, O. Sezer, S. Mu, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem cell transplantation for myelofibrosis: a report from two Canadian centers

W Hasegawa, J. Lipton, D. Hogge, 2003, Bone Marrow Transplantation.

Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.

R. Gascoyne, J. Connors, D. Hogge, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

S. Iida, M. Guckert, A. Oriol, 2016 .

Quantitation, mobilization, and clinical use of long-term culture-initiating cells in blood cell autografts.

C. Eaves, P. Lansdorp, A. Eaves, 1995, Journal of hematotherapy.

Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long‐term proliferation in vitro

R. Zapf, S. Vercauteren, A. Blair, 2001, British journal of haematology.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

A. Jakubowiak, A. Krishnan, S. Lonial, 2016, The Lancet.

Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide.

D. Reece, S. Nantel, M. Barnett, 1993, Leukemia & lymphoma.

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

M. Dimopoulos, S. Iida, A. Belch, 2018, Haematologica.

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2021 .

Excellent real‐world outcomes of adults with Burkitt lymphoma treated with CODOX‐M/IVAC plus or minus rituximab

L. Sehn, J. Connors, G. Slack, 2018, British journal of haematology.

Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.

R. Gascoyne, L. Sehn, J. Connors, 2015, Clinical lymphoma, myeloma & leukemia.

High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumours.

D. Reece, N. Murray, S. Nantel, 1993, British Journal of Cancer.

Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.

R. Gascoyne, J. Connors, D. Hogge, 2004 .

Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.

M. Power, R. Broady, D. Hogge, 2019, Clinical lymphoma, myeloma & leukemia.

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

R. Gascoyne, J. Connors, D. Reece, 2005, Blood.

Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.

D. Horsman, H. Bruyèrè, D. Hogge, 2006, Cancer genetics and cytogenetics.

Deep and Durable Responses in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM) Treated with Monotherapy GSK2857916, an Antibody Drug Conjugate Against B-Cell Maturation Antigen (BCMA): Preliminary Results from Part 2 of Study BMA117159

S. Trudel, P. Richardson, Zangdong He, 2017 .

High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.

R. Gascoyne, J. Connors, D. Hogge, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.

D. Hogge, Clayton A. Smith, S. Nantel, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.

M. Power, Yunfeng Dai, D. Hogge, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.

M. Power, R. Broady, D. Hogge, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.

C. Eaves, A. Eaves, D. Hogge, 1994, Bone marrow transplantation.

Specific binding and release of cells from beads using cleavable tetrameric antibody complexes.

P. Lansdorp, T. Thomas, H. Sutherland, 1989, Journal of immunological methods.

72 Allogeneic bone marrow transplantation for myelofibrosis due to agnogenic myeloid metaplasia (AMM) and essential thrombocytosis (ET): Experience of two bone marrow transplant centers

J. Lipton, D. Hogge, S. Nantel, 2003 .

Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.

D. Horsman, D. Hogge, Y. Chalandon, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of the microenvironment in promoting angiogenesis in acute myeloid leukemia

A. Karsan, K. Leong, R. Zapf, 2002, American journal of hematology.

Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia

R. Gascoyne, L. Sehn, J. Connors, 2013 .

Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML

M. Power, S. Nantel, K. Song, 2008, Bone Marrow Transplantation.

Autografting in chronic myeloid leukemia with cultured marrow.

C. Eaves, P. Lansdorp, D. Reece, 1992, Leukemia.

Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2020 .

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

M. Dimopoulos, J. Miguel, S. Iida, 2019, Journal of Clinical Oncology.

Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

J. Rossi, P. Sonneveld, S. Jagannath, 2007 .

Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.

M. Power, R. Broady, D. Hogge, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

P. Sonneveld, A. Nagler, R. Hájek, 2016, Cancer.

progenitor cells Characterization of a hierarchy in human acute myeloid leukemia

R. Zapf, A. Blair, H. Sutherland, 2011 .

Recurrent idiopathic acute hepatitis-associated aplastic anemia/pancytopenia fourteen years after initial episode.

E. Yoshida, H. Sutherland, H. Wiesinger, 2010, Annals of hepatology.

Weight gain during adjuvant chemotherapy for breast cancer

N. Boyd, K. Heasman, H. Sutherland, 2005, Breast Cancer Research and Treatment.

in the first 100 patients treated in Vancouver primary refractory or relapsed Hodgkin lymphoma: long-term outcome High-dose chemotherapy and autologous stem cell transplantation for

R. Gascoyne, J. Connors, D. Reece, 2011 .

A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.

D. Siegel, P. Richardson, O. Sezer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer.

A. Oza, G. Dranitsaris, H. Sutherland, 1997, Gynecologic oncology.

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

S. Trudel, D. Reece, R. Kotb, 2022, Blood.

Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy

A. Tantiworawit, M. Power, R. Broady, 2012, Leukemia & lymphoma.

Acute monocytic leukemia: a single institution experience.

D. Horsman, D. Reece, H. Fung, 1995, Leukemia & lymphoma.

Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study

N. Murray, D. Hogge, M. Seftel, 2011, Bone Marrow Transplantation.

Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: POLLUX

M. Dimopoulos, S. Iida, A. Belch, 2017 .

Allografting in chronic myeloid leukemia with cultured marrow: Update of the vancouver study

C. Eaves, P. Lansdorp, D. Reece, 1993, Stem cells.

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

S. Tuchman, N. Callander, M. Leiba, 2021, Blood.

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

S. Trudel, D. Reece, R. Kotb, 2021, Blood.

Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).

A. Krishnan, S. Singhal, A. Belch, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

S. Tuchman, N. Callander, G. Schiller, 2022, Blood.

Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment

S. Tuchman, N. Callander, G. Schiller, 2021, EJHaem.

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

S. Tuchman, N. Callander, G. Schiller, 2021, Blood.

Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

J. Shah, S. Tuchman, N. Callander, 2020 .

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

M. Dimopoulos, S. Iida, A. Oriol, 2020, Blood Cancer Journal.

Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)

J. Shah, S. Tuchman, N. Callander, 2020 .

Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).

S. Tuchman, N. Callander, G. Schiller, 2020 .

Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation

F. Kuchenbauer, M. Power, S. Nantel, 2021, Blood.

First in Human Study with GSK2857916, an Antibody Drug Conjugated to Microtubule-Disrupting Agent Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Results from Study BMA117159 Part 1 Dose Escalation

S. Trudel, P. Richardson, Zangdong He, 2016 .

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

P. Sonneveld, A. Nagler, R. Hájek, 2011, Clinical lymphoma, myeloma & leukemia.

Ontario familial colon cancer registry: methods and first-year response rates.

S. Gallinger, M. Cotterchio, H. Sutherland, 2000, Chronic diseases in Canada.

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

D. Sullivan, G. Schiller, M. Sebag, 2018, Blood.

D. Reece, S. Nantel, M. Barnett, 1994, Bone Marrow Transplantation.

Manipulation of the hematopoietic stem cell in vitro.

C. Eaves, C. Udomsakdi, D. Hogge, 1992, Leukemia.

Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117).

H. Sutherland, A. Blair, H. Sutherland, 2000, Experimental hematology.

Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo.

P. Lansdorp, L. Ailles, D. Hogge, 1997, Blood.

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Shang-Yi Huang, Ajai Chari, Chb, 2013 .

Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-.

D. Hogge, H. Sutherland, A. Blair, 1998, Blood.

Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

J. Shah, S. Tuchman, N. Callander, 2019, Blood.

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

J. Shah, S. Tuchman, G. Schiller, 2019, Clinical Lymphoma, Myeloma & Leukemia.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

S. Iida, A. Oriol, P. Moreau, 2017 .

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

S. Tuchman, G. Schiller, R. Kotb, 2023, Clinical lymphoma, myeloma & leukemia.

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

M. Dimopoulos, S. Jagannath, P. Richardson, 2021, Blood.

Growth factor regulation of the maintenance and differentiation of human long-term culture-initiating cells (LTC-IC).

C. Eaves, D. Hogge, H. Sutherland, 1993, Leukemia.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

P. Richardson, O. Sezer, S. Mu, 2013, Journal of Clinical Oncology.

Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers.

C. Eaves, P. Lansdorp, A. Eaves, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Molecular Analysis of Primitive Hematopoietic Cell Proliferation Control Mechanisms a

C. Eaves, R. Humphries, J. Cashman, 1991, Annals of the New York Academy of Sciences.

Organochlorine levels in plasma and risk of multiple myeloma

J. Spinelli, A. Leblanc, K. Song, 2016 .

High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

J. Yeung, M. Power, D. Hogge, 2009 .

High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

R. Gascoyne, J. Connors, D. Reece, 2005, Blood.

Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length

Amanda M Li, R. Schreiber, S. Stockler-Ipsiroglu, 2018, Pediatric hematology and oncology.

Treatment of acute promyelocytic leukemia in patients presenting at Vancouver General Hospital from 1983 to 1992.

D. Horsman, J. Spinelli, D. Reece, 1995, Leukemia & lymphoma.

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma

P. Sonneveld, J. Miguel, A. Nagler, 2014 .

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

M. Dimopoulos, S. Iida, A. Belch, 2018, Haematologica.

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months)

J. Connors, M. Power, R. Broady, 2011, Leukemia & lymphoma.